Burning Rock Biotech (BNR) Research & Development (2019 - 2026)

Burning Rock Biotech (BNR) has reported Research & Development for 8 consecutive years, with -$4.0 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Research & Development rose 28.22% year-over-year to -$4.0 million; the TTM figure through Mar 2026 stood at -$21.8 million (up 24.1% YoY), while the FY2025 annual figure was $23.8 million, down 25.19% from the prior year.
• Research & Development came in at -$4.0 million for Q1 2026 at Burning Rock Biotech, up from -$5.0 million in the prior quarter.
• The five-year high for Research & Development was -$4.0 million in Q1 2026, with the low at -$18.8 million in Q1 2022.
• Average Research & Development over 5 years is -$10.1 million, with a median of -$9.1 million recorded in 2024.
• Across the five-year window, Research & Development plunged 59.53% in 2022 and surged 39.1% in 2025, its largest moves.
• Year by year, Research & Development stood at -$14.6 million in 2022, then climbed by 29.55% to -$10.3 million in 2023, then soared by 30.56% to -$7.2 million in 2024, then soared by 30.29% to -$5.0 million in 2025, then rose by 19.88% to -$4.0 million in 2026.
• According to Business Quant data, Research & Development over the past three periods registered -$4.0 million, -$5.0 million, and -$5.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.